Bicyclo Patents (Class 514/756)
  • Patent number: 10464887
    Abstract: The present invention provides a method for producing an active ingredient for a rivastigmine free base transdermal patch having preparing a rivastigmine free base; and adding an acidic substance to the rivastigmine free base and subjecting the acidic substance and the rivastigmine free base to a mixed reaction to form a mixture having a pH value from 6.0 to 8.5 as the active ingredient; and a rivastigmine free base transdermal patch having a drug layer comprising the active ingredient. The rivastigmine free base transdermal patch has a stable transdermal transmission time equal to or longer than 48 hours and equal to or less than 168 hours. The active ingredient produced by the method and the transdermal patch having the active ingredient allow effective and smooth release of rivastigmine free base and prolongs the release time to meet the clinical application needs.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: November 5, 2019
    Inventor: Tsung-Min Hsu
  • Patent number: 9999590
    Abstract: The subject invention provides improved diclofenac gel formulations.
    Type: Grant
    Filed: July 4, 2013
    Date of Patent: June 19, 2018
    Assignee: Ferring B.V.
    Inventors: Arnaud Grenier, Dario N. Carrara
  • Patent number: 9949935
    Abstract: Rivastigmine transdermal compositions are provided. Aspects of the transdermal compositions include an active agent layer which includes rivastigmine and a solubility modulator, e.g., crosslinked acrylic acid polymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: April 24, 2018
    Assignee: Teikoku Pharma USA, Inc.
    Inventor: Kensuke Murata
  • Publication number: 20150126476
    Abstract: The present invention relates to the use of topical compositions containing bromociclen for the prevention and/or treatment of various types of dermatitis, in particular eczema and psoriasis.
    Type: Application
    Filed: January 2, 2015
    Publication date: May 7, 2015
    Inventor: Carmelo Cutrupi
  • Patent number: 8729092
    Abstract: The invention discloses a method for the treatment of diseases, particularly those diseases characterized by diminished or aberrant cellular function, including AIDS, cancer, and Alzheimer's Disease. The method comprises administering a therapeutically effective amount of rosuvastatin enantiomer compounds in their (3R,5R), (3S,5R), or (3S,5S) configurations, or pharmaceutically acceptable salts thereof. Biologically-active rosuvastatin enantiomer compounds with (3R,5R), (3S,5R), and (3S,5S) stereochemistry are also disclosed.
    Type: Grant
    Filed: September 24, 2012
    Date of Patent: May 20, 2014
    Inventor: Terence J. Scallen
  • Patent number: 8673984
    Abstract: Perfluorocarbon emulsions having a high stability and good oxygen release are disclosed and described. These perfluorocarbon emulsions are typically for use as artificial oxygen carriers. The perfluorocarbon emulsions include a disperse phase of a perfluorocarbon and an emulsion stabilizer, and continuous phase. The emulsion stabilizer can primarily include a poly(ethylene oxide) block copolymer. These stabilized perfluorocarbon emulsions can be used in liquid and/or hydrogel phases of perfusion bioreactors or various other culture systems to enhance cell viability in thick tissue constructs, or as blood substitutes, although other applications may also be considered.
    Type: Grant
    Filed: December 8, 2009
    Date of Patent: March 18, 2014
    Assignee: University of Utah Research Foundation
    Inventors: Natalya Y. Rapoport, Glenn D. Prestwich, Russell Morris Condie
  • Publication number: 20120225102
    Abstract: A perfluorocarbon gel composition is disclosed with numerous uses including topical medical and cosmetic uses.
    Type: Application
    Filed: April 16, 2012
    Publication date: September 6, 2012
    Inventors: Gerald Klein, Richard Kiral, Chris J. Stern
  • Publication number: 20110223243
    Abstract: The invention relates to dispersions of artificial oxygen carriers, wherein the dispersions contain capsules with reversible oxygen storage capacity, the capsules comprising an oxygen-permeable capsule material, that contains and/or encloses fluorinated, particularly perfluorinated hydrocarbons, preferably perfluorocarbons. The dispersions are particularly suitable as a blood substitute, preferably for the purpose of transfusion, e.g. in states of blood loss of the human or animal body, in particular following surgical interventions, accidents, injuries etc, or for the prophylactic treatment and/or treatment by therapy of ischaemic states or states following a reperfusion.
    Type: Application
    Filed: July 8, 2009
    Publication date: September 15, 2011
    Inventors: Herbert De Groot, Christian Mayer, Frank Petrat, Michael Kirsch
  • Publication number: 20110027384
    Abstract: The present invention provides a photosensitising composition comprising a mixture of at least one oxygen carrier, at least one oxidising agent and at least one surfactant, and its uses. The ratio of the at least one oxygen carrier to the at least one oxidising agent to the at least one surfactant may be in the range of 50:40:10 to 80:19.8:0.2. The photosensitising composition may be used for treating and/or preventing conditions caused by microorganisms.
    Type: Application
    Filed: April 6, 2009
    Publication date: February 3, 2011
    Applicant: National University of Singapore
    Inventors: Anil Kishen, Saji George
  • Publication number: 20100267842
    Abstract: The subject application provides for an emulsion comprising an amount of a perfluorocarbon liquid dispersed as particles within, a continuous liquid phase, wherein the dispersed particles have a monomodal particle size distribution and uses thereof. The subject application also provides for a method of manufacturing a perfluorocarbon emulsion, a process for preparing a pharmaceutical product containing a PFC emulsion and a process for validating a batch of an emulsion for pharmaceutical use.
    Type: Application
    Filed: April 15, 2010
    Publication date: October 21, 2010
    Inventors: Richard Kiral, Deborah P. Thompson, Gary L. Clauson
  • Patent number: 7488854
    Abstract: The present invention provites a compound having the following structure: wherein, in the formula: X is selected from the group consisting of hydroxy, substituted hydroxy, halogen, thiol, and substituted thiol; one of Y1 and Y2 is hydrogen or alkyl, and the other is Z-W, wherein Z is a single bond, or a divalent group having alkane or substituted alkane having two hydrogen atoms removed, and W is hydroxy, substituted hydroxy, aldehyde, carboxyl, or substituted carboxyl; and R1-R24 are independently selected from the group of hydrogen, alkyl, and substituted alkyl.
    Type: Grant
    Filed: March 12, 2003
    Date of Patent: February 10, 2009
    Assignees: The National Institute of Agrobiological Sciences, Riken
    Inventors: Shigemi Seo, Yuko Ohashi, Hideharu Seto, Shigeo Yoshida
  • Publication number: 20080075710
    Abstract: An herbal composition is adapted to treat hangovers. In one embodiment, the herbal composition comprises potassium, thiamin (vitamin B-1), magnesium, silymarin and N-acetyl-L-cysteine (acetylcysteine), or any pharmaceutically acceptable salts thereof. In a method of treating hangovers, an herbal composition is provided that comprises potassium, thiamin, magnesium, silymarin and N-acetyl-L-cysteine. The herbal composition is placed in the body so as to alleviate or reduce the effects of a hangover.
    Type: Application
    Filed: September 11, 2007
    Publication date: March 27, 2008
    Inventors: Erik T. Cornett, Gerad A. Harsy
  • Patent number: 7252845
    Abstract: Novel compositions of matter containing aromatic compounds and terpenoids which are present in and may preferably be derived from the plant Alpinia galanga (Zingiberaceae) show synergistic effects with respect to immunomodulation, and they significantly suppress hypersensitivity reactions. Thus they are used for preparing medicaments for these purposes and, more specifically, for the treatment or prevention of IgE mediated allergic reactions and conditions, such as asthma, allergic rhinitis, atopic eczema or anaphylaxis, and autoimmune disorders, such as Crohn's disease, ulcerative colitis, rheumatoid arthritis or psoriasis, as well as for the alleviation of pain. They can for example be formulated into pharmaceuticals, cosmetics or dietary supplements. A method of preparing such compositions from Alpinia galanga is also described.
    Type: Grant
    Filed: January 2, 2003
    Date of Patent: August 7, 2007
    Assignee: Ferrosan A/S
    Inventors: Morten Sloth Weidner, Morten Just Petersen, Nina Worm Jensen
  • Publication number: 20040266889
    Abstract: A method of forming an end seal (50) for a manufactured seed (22) is provided. The method includes providing a manufactured seed having an open-end (56) and immersing at least the open end of the manufactured seed in a sealing material (54) for a predetermined period of time. The method also includes permitting the sealing material to harden over the opened end of the manufactured seed to form a plug that seals the opened end.
    Type: Application
    Filed: May 24, 2004
    Publication date: December 30, 2004
    Inventor: Edwin Hirahara
  • Patent number: 6444700
    Abstract: In its broadest aspect, the present invention is directed to the discovery of immunonutritional products that are useful in reducing the immunological system suppression that results from stress. The stress may be in the form of physical exertion, mental exhaustion, disease states and the like. In one embodiment, the invention relates to a nutritional composition comprising a structured glyceride component and an antioxidant system. This nutritional composition has been shown to be highly effective in reducing immune system down regulation or dysregulation as a result of stress.
    Type: Grant
    Filed: March 19, 2001
    Date of Patent: September 3, 2002
    Assignee: Abbott Laboratories
    Inventors: Stephen J. DeMichele, John W. McEwen, Steven M. Wood
  • Patent number: 6337337
    Abstract: A method for treating disorders responsive to DHFR inhibition is disclosed, wherein the disorders may include neoplastic diseases, rheumatoid arthritis, restenosis, multiple sclerosis, lupus, infections, and ectopic pregnancy. The inventive method comprises administering to a patient in need of treatment a therapeutically-effective amount of a composition comprising certain aromatic, primarily non-aliphatic, molecules that may be found in coal tar.
    Type: Grant
    Filed: September 3, 1999
    Date of Patent: January 8, 2002
    Inventor: Carol J. Buck
  • Patent number: 6235796
    Abstract: Method for the prevention and inhibition of adhesion between tissues comprising the use of fluorocarbons are disclosed. The method provides for the introduction of a fluorocarbon into the surgical site of a mammalian body, such as a human, to minimize friction and enhance the mobility of the surrounding tissues and organs. The fluorocarbons introduced may be in various forms including liquid and emulsions, and provides a coating, film or barrier thereby reducing the surface tension associated after surgery. The subject invention further discloses the use of perfluorodecalin as a preferred fluorocarbon compound used as the primary anti-adhesion agent.
    Type: Grant
    Filed: June 26, 2000
    Date of Patent: May 22, 2001
    Inventor: Sarfaraz K. Niazi
  • Patent number: 5859068
    Abstract: A method for the acceleration of tissue growth using continuous fluorocarbon liquid-based positive pressure is disclosed, whereby significant increase in tissue growth is achieved.
    Type: Grant
    Filed: February 24, 1995
    Date of Patent: January 12, 1999
    Assignee: Children's Medical Center Corporation
    Inventor: Jay M. Wilson
  • Patent number: 5824703
    Abstract: A method of assisting a mammal having a lung disorder to breathe ambient gas normally, i.e., without the assistance of a ventilator. The method includes providing an animal having a lung disorder, such as surfactant deficiency, stiff lung, or hyperinflated lung syndrome, and instilling a minimum effective dose of a perfluorochemical liquid or emulsion through the trachea for coating the alveolar sacs of a lung of the mammal. The preferred perfluorochemicals have a very low vapor pressure to avoid inducing hyperinflated lung syndrome and are supplied in a minimum effective dosage sufficient to coat the inner lung surfaces. The perfluorochemicals are permeable to the ambient gas and reside substantially permanently within the alveolar sacs without inducing hyperinflated lung syndrome. The liquid is instilled in an amount sufficient to enable the animal to breathe the ambient gas normally with O.sub.2 /CO.sub.2 blood gas exchange. Effective coating of the lungs with a small (generally <0.
    Type: Grant
    Filed: December 27, 1996
    Date of Patent: October 20, 1998
    Assignee: Synthetic Blood International, Inc.
    Inventor: Leland C. Clark, Jr.
  • Patent number: 5684050
    Abstract: Stable emulsions of highly fluorinated organic compounds for use as oxygen transport agents, "artificial bloods" or red blood cell substitutes and as contrast agents for biological imaging. The emulsions comprise a highly fluorinated organic compound, an oil that is not substantially surface active and not significantly soluble in water, a surfactant and water.
    Type: Grant
    Filed: May 15, 1995
    Date of Patent: November 4, 1997
    Assignee: HemaGen/PFC
    Inventors: Leland C. Clark, Jr., Robert Francis Shaw
  • Patent number: 5674913
    Abstract: A method of assisting a mammal having a lung disorder to breathe ambient gas normally, i.e., without the assistance of a ventilator. The method includes providing an animal having a lung disorder, such as surfactant deficiency, stiff lung or hyperinflated lung syndrome, and instilling a perfluorochemical liquid into the trachea for administration in the alveolar sacs of a lung of the animal. The perfluorochemical is permeable to the ambient gas and resides substantially permanently within the alveolar sacs without inducing hyperinflated lung syndrome. The liquid is instilled in an amount sufficient to enable the animal to breathe the ambient gas normally with O.sub.2 /CO.sub.2 blood gas exchange. In another aspect of the invention, the method further includes the step of alleviating the lung disorder without inducing hyperinflated lung syndrome.
    Type: Grant
    Filed: May 13, 1994
    Date of Patent: October 7, 1997
    Assignee: Synthetic Blood International, Inc.
    Inventor: Leland C. Clark, Jr.
  • Patent number: 5635539
    Abstract: Stable emulsions of highly fluorinated organic compounds for use as oxygen transport agents, "artificial bloods" or red blood cell substitutes and as contrast agents for biological imaging. The emulsions comprise a highly fluorinated organic compound, an oil that is not substantially surface active and not significantly soluble in water, a surfactant and water.
    Type: Grant
    Filed: May 23, 1996
    Date of Patent: June 3, 1997
    Assignee: HemaGen/PFC
    Inventors: Leland C. Clark, Jr., Robert F. Shaw
  • Patent number: 5573757
    Abstract: Compositions for topical application in gel form comprising a fluorocarbon or perfluorocarbon compound or mixtures thereof at a concentration of at least about 75% v/v, a minor quantity of a surface active agent and an aqueous phase.The compositions provide a storage-stable high concentration fluorocarbon gel that is prepared without the use of thickeners or additional stabilizing agents. The gels are useful in formulations for pharmaceutical, cosmetic purposes and for other products as well.
    Type: Grant
    Filed: October 3, 1994
    Date of Patent: November 12, 1996
    Assignee: Alliance Pharmaceutical Corp.
    Inventors: Jean G. Riess, Marie-Pierre Krafft
  • Patent number: 5565460
    Abstract: The present invention relates to a therapeutic agent for Parkinson's disease containing as an active ingredient a polycyclic compound or a pharmaceutically acceptable salt thereof, the compound being represented by the following Formula (I): ##STR1## and A represents N or CR.sup.5 (in which R.sup.5 represents hydrogen, or substituted or unsubstituted lower alkyl), or represented by the following Formula (II): ##STR2## wherein Y, R.sup.6 and R.sup.8 are as defined herein and B and the adjacent two carbon atoms are combined to form a substituted or unsubstituted, partially saturated or unsaturated, monocyclic or bicyclic, carbocyclic or heterocyclic group.
    Type: Grant
    Filed: March 3, 1995
    Date of Patent: October 15, 1996
    Assignee: Kyowa Hakko Koygo Co., Ltd.
    Inventors: Fumio Suzuki, Junichi Shimada, Nobuaki Koike, Shunji Ichikawa, Joji Nakamura, Tomoyuki Kanda, Shigeto Kitamura
  • Patent number: 5374624
    Abstract: The present invention relates to fluorochemical blood substitutes used for preserving mammalian tissue having lysophosphatidyl compounds in non-toxic concentrations. More specifically, the invention relates to aqueous fluorochemical emulsions of a fluorochemical and an emulsifier useful as oxygen delivery agents and methods of preserving tissue in investigational and clinical settings, particularly those settings involving in in vivo transfusion, cardiac and other organ preservation, and in vitro organ perfusion.
    Type: Grant
    Filed: August 11, 1993
    Date of Patent: December 20, 1994
    Inventor: Leigh D. Segel
  • Patent number: 5270345
    Abstract: Novel pesticidal compositions, which are characterized by biodegradability and do not bioaccumulate to an unacceptable level in fats and tissues of animals, fowl and fish, containing active compounds and optionally a carrier suitable for administering said compounds to a pest by contact, ingestion or inhalation, are disclosed. Such compositions comprise in addition to the carrier compounds of the formula ##STR1## where R is H, Cl or other Hal, hydroxyl, lower alkoxyl, lower alkyl, cyano, CONR.sub.2 or NR.sub.2 where R.sub.
    Type: Grant
    Filed: May 3, 1991
    Date of Patent: December 14, 1993
    Assignee: Coulston International Corporation
    Inventor: Frederick Coulston
  • Patent number: 5104900
    Abstract: A new use for naphthalene comprising a snake repellant in the form of granules comprising 8% naphthalene, 32% sulfur and 60% montmorillonite. The compound is spread in a strip across an area where snakes are to be repelled and is effective against venomous and non-venomous varieties.
    Type: Grant
    Filed: February 28, 1990
    Date of Patent: April 14, 1992
    Inventor: James B. Tennyson
  • Patent number: 5073383
    Abstract: Aggregation of fluorocarbon emulsion particles, which occurs when the emulsion mixes with blood, is reduced by the addition of relatively large amounts of phosphate.
    Type: Grant
    Filed: April 21, 1989
    Date of Patent: December 17, 1991
    Assignee: Affinity Biotech, Inc.
    Inventor: Robert T. Lyons
  • Patent number: 5061484
    Abstract: A stable perfluorochemical emulsion is provided which comprises perfluorochemical particles in stabilized vesicles. The vesicles comprise a biocompatible polymer formed by coating the perfluorochemical particles with one or more phospholipid monomer(s) and polymerizing the monomer(s).
    Type: Grant
    Filed: March 10, 1989
    Date of Patent: October 29, 1991
    Assignee: Alpha Therapeutic Corporation
    Inventor: Charles M. Heldebrant
  • Patent number: 4917930
    Abstract: Compositions having enhanced gas and drug transporting capability, are prepared by providing a perfluoro compound dispersed in an aqueous medium with a surfactant to form an aqueous initial dispersion, concentrating the perfluoro compound phase of the dispersion as by centrifugation or filtration, wherein a portion of the surfactant remains complexed with the particles of the perfluoro compound phase and the balance of the surfactant is in the aqueous phase, separating the phases, and redispersing the particles of the concentrated perfluoro compound phase to form a final dispersion in which greater than 65% by weight, and preferably at least 75%, of the surfactant present is complexed with the perfluoro compound particles.
    Type: Grant
    Filed: October 3, 1986
    Date of Patent: April 17, 1990
    Assignee: Adamantech, Inc.
    Inventor: William McCormick
  • Patent number: 4895876
    Abstract: A stable concentrated aqueous emulsion of perfluorochemical, a phospholipid and a triglyceride of fatty acids has been demonstrated which has enhanced stability, diminished particle size and heightened tolerance by biological systems. The emulsion has utility as an oxygen transport medium, such as artificial blood. The emulsion can optionally include additional emulsifiers of SURFYNOL.RTM.SE surfactant and PLURONIC.RTM. P-105 surfactant. The emulsion is produced using an improved emulsification technique. The invention includes methods of oxygen transport in vascular systems wherein the oxygen carrying capacity of the vascular systems is improved with the emulsions of the present invention. Methods are also described for organ preservation extra-vivo by perfusing, suffusing, flushing and filling organs outside the body with the oxygen carrying emulsions of the present invention.
    Type: Grant
    Filed: March 20, 1987
    Date of Patent: January 23, 1990
    Assignee: Air Products and Chemicals, Inc.
    Inventors: Frank K. Schweighardt, Charles R. Kayhart
  • Patent number: 4879062
    Abstract: An inert, water-immiscible inert organic liquid having gas transport properties, water and a suitable emulsifying agent are formed into a stable gel by emulsifying a mixture of the same, concentrating the emulsion to form a gel phase and a liquid phase and separating the two phases. The resulting gel can be used as an ointment or cosmetic for skin irritations or wounds, or as a coating in industrial applications where extended contact of a surface with a gas, such as oxygen, is desired. Fluorocarbons or low viscosity silicone oils are suitable organic liquid components of the gels.
    Type: Grant
    Filed: September 19, 1985
    Date of Patent: November 7, 1989
    Assignee: Adamantech, Inc.
    Inventor: Robert E. Moore
  • Patent number: 4866096
    Abstract: A stable aqueous emulsion of perfluorochemical, a phospholipid and a triglyceride of fatty acids has been demonstrated which has enhanced stability, diminished particle size and heightened tolerance by biological systems. The emulsion has utility as an oxygen transport medium, such as artificial blood.
    Type: Grant
    Filed: March 20, 1987
    Date of Patent: September 12, 1989
    Assignee: Air Products and Chemicals, Inc.
    Inventor: Frank K. Schweighardt
  • Patent number: 4569943
    Abstract: The compound of the formula: ##STR1## wherein R.sub.1 is hydrogen, methyl or hydroxymethyl, R.sub.2 is hydrogen or methoxy, R.sub.3 is hydroxy or methoxy, and R.sub.4 is hydrogen or a group ##STR2## is novel, and the compound is of use as inhibitors of animal tissue fibrosis, or biochemical reagents.
    Type: Grant
    Filed: October 19, 1983
    Date of Patent: February 11, 1986
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Hisayoshi Okazaki, Kazuhiko Ohta, Takenori Ishimaru
  • Patent number: 4497829
    Abstract: Particles of perfluoro compound with a lipid coating are emulsified by sonification in aqueous medium, wherein the proportion of perfluoro compound in the emulsion is preferably about 30-75% (w/v) and the proportion of lipid is preferably about 7-9% (w/v). In the resulting stable emulsion 95% of these particles having diameters less than 0.2.mu.. The emulsion is useful as an artificial blood for transport and delivery of oxygen to body tissues.
    Type: Grant
    Filed: August 19, 1983
    Date of Patent: February 5, 1985
    Assignee: The University of Pennsylvania
    Inventor: Henry A. Sloviter